Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2025

New molecules in the therapy of chronic graft-versus-host disease.

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLaurenz SteinerSKStefan KleinSKSebastian Kreil

Discussion

Loading...

Member takes

Overview

Multiple novel agents improve outcomes in chronic graft-versus-host disease, highlighting critical safety and therapeutic sequencing considerations.

Key Points

  • Novel compounds improve outcomes and offer new treatment strategies for chronic graft-versus-host disease.
  • Approved therapies include ibrutinib and ruxolitinib after first-line treatments, suggesting effective sequencing options.
  • Immunosuppressive treatment choices depend on organ involvement and prior therapies, indicating a personalized approach is necessary.
  • Targeted therapies may help manage chronic inflammation and fibrosis, emphasizing the potential for more effective combinatorial strategies.

Cite This Study

Steiner et al. (2025) studied this question.

synapsesocial.com/papers/689fc962e46e096235ce1cc8https://doi.org/10.1097/moh.0000000000000893
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1[Therapeutic strategies for graft-versus-host disease in the new era].2025
  2. 2Biochemical markers and emerging therapies for intestinal manifestation of graft-versus-host disease2025 · 2 citations
  3. 3Clinical trials in graft-versus-host disease: changes in study characteristics, investigated drugs, and endpoints over time2026
  4. 4Successful use of ruxolitinib in steroid-refractory chronic GvHD affecting central nervous system: a case report2026
  5. 5Expanding Role of Gastroenterologists in Acute Gastrointestinal Graft-versus-Host Disease: From Diagnosis and Management to Microbiome-Based Strategies2025